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Harlequin Ichthyosis Is Biochemically Heterogeneous 
Previous attempts to identify dle basic biochemical defect underly-
ing harlequin ichthyosis have by and large been unsuccessful. The 
studies produced inconsistent resules, but they were also handi-
capped by a major limitation. Harlequin ichthyosis is an extremely 
rarc genetic disease, and each study included only one or rwo pa-
tients at most. In this issue, however, a group of researchers from the 
University of Was hingt on in Seattle describes new results (harshow 
that harlequin ichthyosis is biochemically heterogeneous even 
though the clinical symptoms of affected individuals are very sim-
ilar. 
In conrrast to previous studies, this one included tissue samples 
from nine infants and one fetus affected with the disease. "One of 
the fhings that was very fortunate was that so many clinical people 
were willing to send us samples," says Beverly Dale of the Seattle 
group. The results of D,ale and her colle,agues Karen Holbrook, 
Philip Fleckman, Janet Kimball, Steve Brumbaugh, and Virginia 
Sybert help [0 explain why those of the previous studies were incon-
sistent, as well as providing information that may eventually lead to 
bcner treatments for the disease. 
The Seattle workers looked for abnormalities in rwo rypcs of 
protein, the filaggrins and keratins, in skin samples from the harle-
quin ichthyosis patients. They found that the affected skin showed 
three differem patterns of abnormalities. The pattern type may be 
genetically determined, Dale says. Affected siblings were available 
in ~vo families. and in both families the second sibling had the same 
abnormality pattern as the first. 
Despite having different protein abnonnalities. the skin samples 
from the harlequin ichthyosis patients had a common morphologic 
defecL "The lamellar granules were defective or absent," Dale says. 
This defect may be what causes the thickened skin characteristic of 
harlequin ichthyosis. The lamellar granules are needed to form the 
normal skin lipids, which arc involved in rhe shedding of cells from 
the stratum corneum. The skin thickening may therefore be marc 
the result of failure to shed cells than of increased skin cell prolifera-
tion, although thac may also contribute, Dale says. So far, however, 
the Seattle wotkers do not know what the connection might be 
between the protein abnormalities and the lamellar granule defect, 
Analysis of the genetic heterogeneity of harlequin ichthyosis may 
eventually lead to better treatments for the disease. "There is at least 
the possibility that one type might be more treatable than rhe 
others," Dale says. "We don't know that yet. But we at least have 
some handle on the genetic hcterogenciry, and we hope it will help 
us in the future." 
UV -Irradiated Keratinocytes Release Specific Immunosuppressive Factors 
When ultraviolet radiation S[rikes the skin it causes the suppression 
of certain specific immune responses, and not just in the vicinity of 
the irradiated skin. The immune responses arc suppressed through-
out the body, an effect that may contribute to the ability of UV 
radiation to induce skin cancers. How the radiation suppresses sys-
temic immune responses is still a mystery. In this issue, however, 
Tae-Yoon Kim, Margaret Kripke, and Stephen Ullrich of the Uni-
versity of Texas M.D. Anderson Cancer Center in Houston provide 
new data in support of the hypothesis that the systemic immune 
effects ofUV irradiation might be mediated by diffusible, immuno-
suppressive facmrs released by irradiated skin cells. Somewhat sur-
prisingly, the researchers found that UV A and UVB radiation may 
cause thc release of factors with different immunosuppressive ef-
fects. The work may lead to ways of preventing or treating UV-in-
duced skin cancers and also ro better methods of warding off graft 
rejection. 
Ullrich and his co-workers undertook the current investigations 
to follow-up an observation made a few years ago by Thomas 
Schwarz and his colleagues in Vienna. The Viennese workers had 
shown that UV irradiation might be causing its immune effects by 
triggering the release by keratinocyres of factors that could diffuse 
through the body and suppress systemic immune responses. 
Ullrich's idea was to irradiate cultured keratinocytes and then see 
what happens when culture fluid from the cells was injected into 
living mice. If UV irradiation causes the release ofimmunosuppres-
sive factors, Ullrich explains, "then this should mimic what hap-
pens when the animals are irradiated." 
And that was what the Houston workers found-up to a point. 
UV irradiation is selective in its effects, suppressing some immune 
responses but not others. Two of the responses affected arc dclayed-
rype hypersensitivity and contact hypersensitiviry. "We found that 
we could suppress delayed hypersensitivity bur we couldn't suppress 
contact hypersensitivity," Ullrich says. "This was somewhat at var-
iance with what Schwarz found. We were really perplexed." 
A fe-reading of the Viennese group's paper revealed a difference 
in experimental technique that might explain the discrepant results. 
The UV light source used by Schwarz and his colleagues produced 
much more UVA radiation than did the lamp used by the Houston 
workers, which produced mainly UVB radiation. When Ullrich 
and his colleagues then exposed the cultured cells separately to 
UVA and UVB irradiation, they found that super-natenrs from the 
UVA-irradi:Hed cells suppressed contact hypersensitivity, bu t not 
the delayed type, whereas supernatants from the UVB-treated cel ls 
decreased delayed-type hypersensitiviry but not contact hypersensi-
tivity. "It appears that keratinocytes produce different factors in 
response to the different wavelengths," Ullrich says. Both factors 
were apparently produced in rhe Viennese experiments, while only 
UVB factor was made in significant amounts in the Houston exper-
iments. 
The next step is to try to identify those factors which may have 
clinical applications. The immune reactions that calise delayed-type 
hypersensitivity, for example, arc similar to those that mediate graft 
rejection. It might therefore be possible, Ullrich remarks, to use the 
factor that suppresses delayed-type hypersensitivity to prevent graft 
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rejection without depressing other immune responses needed to 
fight off disease. In addition. understanding the mechanisms under-
lying the immune suppression caused by UV irradiation may also 
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lead to ways of preventing or treating the skin cancers that the 
radiation induces. 
Retinoids Suppress the Activity of a Gene Needed for Cell Proliferation 
The rcrinoids are widely used to treat psoriasis and other skin dis-
eases characterized by increased keratinocyte growth. In this issue. 
David Olsen, Noreen Hickok, andJounj Uitto ofThomasJcfferson 
University in Philadelphia report new results that may help explain 
why the compounds are effective. 
They find that rcrinoids. including aJl-trmlS- and 13-cis-retinoic 
acid , suppress the activity of the gene encoding the enzyme orni-
thine decarboxylase (~OC). This is the key enzyme for the synche-
sis of compounds called polyamines. which arc needed for cell pro-
liferation. "The retinoids very rapidly down-regulate the 
expression of the ODe gene," Uino says. "Th is indicates that cell 
proliferation is suppressed and could explain the mechanism of how 
these compounds work in psoriasis." 
The retinoids apparently do not work directly on the ODe gene, 
however. They have no effect 011 the gene activity in the presence of 
inhibitors of protein synthesis, a result indicating that the com-
pounds act through some as yet unidentified protein. The retinoid 
receptor, which is necessary for the compounds' action in skin. is 
one possible candidate for that intermediate protein. Experiments 
are now in progress to test that hypothesis. Uitco says. 
Increased Oncogene Expression Is Not Central to Psoriasis Pathology 
Psoriatic cells resemble cancer cells in that both proliferate abnor-
mally. But there is also a major difference. The psoriatic cells do nOt 
become malignant and metastasize. In this issue. a group of re-
searchers from the University of Michigan School of Medicine in 
Anll Arbor report the results of experiments in which they looked at 
the expression of a series of five "proto-oncogenes" in psoriatic 
cells. 
Proto-oncogenes normally help to regulate cell growth and dif-
ferentiation. But they have the potential to cause cells to become 
cancerous if they go awry. This may happen, for example. if they 
undergo mutations that change the function of the proteins they 
encode or cause those proteins to be made in higher than normal 
amounts. The Michigan workers. James Elder. Amir Tavakkol, 
Susan Klein, Mary Zeigler, Max Wicha. and J ohn Voorhees, 
wanted to find out if increased proto-oncogene expression caused 
the higher than normal proliferation of psoriatic cells. The answer, 
apparently , is no. 
They compared the five levels of messenger RNA transcribed 
from each of five proto-oncogenes, each of which has a different 
mode of action. in normal and psoriatic skin. All five showed mod-
est increases in expression in the psoriatic skin. The expression of 
two other genes. which have not been linked [0 cancer or excessive 
cell growth, showed similar increases, however. This may indicate, 
Elder says, that the elevated oncogene expression only reflects the 
rapid growth of psoriatic cells, rather than causing it. 
In other experiments, the Michigan group has shown that the 
activiry of another gene, one coding for transforming growth faccor 
alpha. is gready increased-by a factor of 10 to 20-in psoriatic 
cells. That increase is much greater than those seen with the proto-
oncogenes. "We think that this is one of the main mechanisms for 
the run-away chain reaction of psoriatic cel ls," Klein says. The hope 
is that the researchers may be able to find ways of blocking the 
excessive cell proliferation of psoriasis if they can identify its cause. 
The current work suggests that the best way of doing this may be to 
block the synthesis or activity of transforming growth factor alpha. 
rather than going after the proto-oncogenes and their products. 
